Long Term Survivors with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine: A Retrospective Analysis

DSpace/Manakin Repository

Long Term Survivors with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine: A Retrospective Analysis

Citable link to this page

. . . . . .

Title: Long Term Survivors with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine: A Retrospective Analysis
Author: Goulart, Bernardo HL; Grenon, Nina; Muzikansky, Alona; Clark, Jeffrey William; Lauwers, Gregory Y.; Ryan, David P.; Zhu, Andrew Xiuxuan

Note: Order does not necessarily reflect citation order of authors.

Citation: Goulart, Bernardo H. L., Jeffrey W. Clark, Gregory Y. Lauwers, David P. Ryan, Nina Grenon, Alona Muzikansky, and Andrew X. Zhu. 2009. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. Journal of Hematology & Oncology 2: 13.
Full Text & Related Files:
Abstract: Background: Metastatic pancreatic adenocarcinoma has a short median overall survival (OS) of 5–6 months. However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations. Methods: We identified 20 patients with metastatic or recurrent pancreatic adenocarcinoma who received single-agent gemcitabine and had an OS longer than 1 year. Baseline data available after the diagnosis of metastatic or recurrent disease was categorized as: 1) clinical/demographic data (age, gender, ECOG PS, number and location of metastatic sites); 2) Laboratory data (Hematocrit, hemoglobin, glucose, LDH, renal and liver function and CA19-9); 3) Pathologic data (margins, nodal status and grade); 4) Outcomes data (OS, Time to Treatment Failure (TTF), and 2 year-OS). The lowest CA19-9 levels during treatment with gemcitabine were also recorded. We performed a univariate analysis with OS as the outcome variable. Results: Baseline logarithm of CA19-9 and total bilirubin had a significant impact on OS (HR = 1.32 and 1.31, respectively). Median OS and TTF on gemcitabine were 26.9 (95% CI = 18 to 32) and 11.5 (95% CI = 9.0 to 14.3) months, respectively. Two-year OS was 56.4%, with 7 patients alive at the time of analysis. Conclusion: A subgroup of patients with metastatic pancreatic cancer has prolonged survival after treatment with gemcitabine. Only bilirubin and CA 19-9 levels were predictive of longer survival in this population. Further analysis of potential prognostic and predictive markers of response to treatment and survival are needed.
Published Version: doi:10.1186/1756-8722-2-13
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663565/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:5355102

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters